1. Introduction {#sec1-molecules-17-13960}
===============

*Eucommia ulmoides* Oliv. mainly grows along the Yangtze River and in southern China. Its bark has traditionally been applied in China as an antihypertensive, diuretic, sedative, tonic and nourishing agent \[[@B1-molecules-17-13960]\]. The pharmacological effects of *E. ulmoides* are recorded as strengthening the internal organs, bones and muscles, and preventing senescence \[[@B2-molecules-17-13960]\]. The extract of its leaves also showed activities against hypertension and bacteria \[[@B2-molecules-17-13960],[@B3-molecules-17-13960]\]. Previous chemical investigations on this plant have resulted in the isolation of a series of lignanoids \[[@B4-molecules-17-13960],[@B5-molecules-17-13960],[@B6-molecules-17-13960],[@B7-molecules-17-13960]\], phenylpropanolds \[[@B8-molecules-17-13960],[@B9-molecules-17-13960],[@B10-molecules-17-13960]\], iridoids \[[@B9-molecules-17-13960],[@B11-molecules-17-13960]\], flavones \[[@B11-molecules-17-13960],[@B12-molecules-17-13960]\], guttapercha \[[@B2-molecules-17-13960]\], polysaccharides \[[@B2-molecules-17-13960]\], and terpenes \[[@B13-molecules-17-13960],[@B14-molecules-17-13960]\]. As part of a program to study the chemical diversity of traditional Chinese medicines and their biological effects, an ethanol extract of *E. ulmoides* has been investigated. We describe herein the isolation, structure elucidation of a new ursane-type nortriterpenoid, ulmoidol A (**1**), and ten known compounds **2**--**11** from the EtOAc-soluble portion of the ethanol extract of *E. ulmoides* ([Figure 1](#molecules-17-13960-f001){ref-type="fig"}). On the basis of theoretical calculations of its electronic circular dichroism (ECD), the absolute configuration of compound **1** was also established. Compounds **3** and **4** showed inhibition to PTPIB activities with IC~50~ values of 0.69 and 3.98 μM, respectively.

2. Results and Discussion {#sec2-molecules-17-13960}
=========================

Compound **1** was obtained as a white amorphous powder. Its molecular formula was determined as C~29~H~38~O~5~ by HRESIMS (*m/z* 467.2792, \[M+H\]^+^), representing 11 degrees of unsaturation. The presence of hydroxyl (3,407 cm^--1^), *γ*-lactone (1,784 cm^--1^) and conjugated ketone (1,618 cm^--1^) groups was evident from its IR spectrum. The ^1^H-NMR spectrum of **1** ([Table 1](#molecules-17-13960-t001){ref-type="table"}) revealed resonances suggestive of six methyl proton signals at *δ*~H~ 0.97 (3H, s), 0.98 (3H, d, *J* = 5.5 Hz), 1.33 (3H, s), 1.40 (3H, s), 1.18 (3H, d, *J* = 6.5 Hz), and 2.01 (3H, s), two oxygen-bearing methine protons at *δ*~H~ 3.08 (1H, d, *J* = 4.0 Hz) and 3.38 (1H, dd, *J* = 4.0, 2.0 Hz), one olefinic proton at *δ*~H~ 6.47 (lH, brs), and one hydroxyl signal at *δ*~H~ 6.23 (1H, brs). The ^13^C-NMR spectrum revealed 29 carbon resonance signals, including an ester carbonyl (*δ*~C~ 178.83), a conjugated keto carbonyl (*δ*~C~ 181.44), four olefinic carbons (*δ*~C~ 163.62, 144.88, 127.34, and 123.22), and three oxygen-bearing carbons (*δ~C~* 88.67, 54.71 and 54.60). The aforementioned data were indicative of an ursane-type nortriterpenoid skeleton for **1**, similar to those of ulmoidol (**2**) \[[@B14-molecules-17-13960]\]. Compared with compound **2**, the NMR spectral data of compound **1** showed some differences in the A ring, including the absence of two oxygen-bearing carbons and an exo-methylene group, and the presence of a conjugated keto carbonyl, four olefinic carbons and a methyl group, all of which implied the existence of a hexa-1,4-dienone moiety in the A ring of **1**, with the carbonyl at C-3. The above assumption was confirmed by the HMBC correlations of H-1/C-2, C-3, C-5, C-9, C-10 and C-25, and H-23/C-3 and C-5 ([Figure 2](#molecules-17-13960-f002){ref-type="fig"}). The HMBC correlations from *δ*~H~ 6.23 (-OH) to C-1, C-2, C-3 located the hydroxyl group at C-2. The linkage of C-13 and C-28 via a lactone ring was furnished by the carbon chemical shifts of C-18 and C-28, as well as the key HMBC correlations between H-18 and C-13, C-14, and C-28; H-22/C-17 and C-18 and H-16/C-17 and C-28. The HMBC correlations of H-12/C-13 and C-11; H-11/C-10 and C-9 verified the three-member epoxy group at C-11 and C-12, as showed in compound **2**. Moreover, the key ROESY correlations of H-11, H-12/H~3~-26; H-11/H-25 suggested the *α*-orientation of the 11,12-epoxide ([Figure 2](#molecules-17-13960-f002){ref-type="fig"}). The relative configuration of **1** was deduced according to ROESY experiment and the literature \[[@B14-molecules-17-13960],[@B15-molecules-17-13960]\], leading to two possible structures **1a** and **1b** ([Figure 3](#molecules-17-13960-f003){ref-type="fig"}).

The absolute configuration of compound **1** was established by theoretical calculation of its electronic circular dichroism (ECD) using the time-dependent density functional theory (TD-DFT) method \[[@B16-molecules-17-13960]\]. Their optimized geometries were obtained, and then the ECD spectra were calculated at the B3LYP/6-31G(d) level with the TD-DFT/PCM model in methanol solution \[[@B17-molecules-17-13960]\]. As shown in [Figure 4](#molecules-17-13960-f004){ref-type="fig"}, the calculated ECD spectrum of **1a** exhibited a diagnostic negative Cotton effect at around 252 nm, corresponding to the experimental Cotton effect observed at 254 nm. Therefore, the absolute configuration of compound **1** was determined as (11*S*,12*S*)-4-methyl-11,12-epoxy-2-hydroxy-3-oxoursa-1,4-dine-28-oic acid *γ*-lactone (**1a**), and the compound was named ulmoidol A.

Ten known compounds, namely ulmoidol (**2**) \[[@B14-molecules-17-13960]\], corosolic acid (**3**) \[[@B18-molecules-17-13960]\], 2*α*,3*α*-dihydroxy-24-nor-4(23), 12-oleanadien-28-oic acid (**4**) \[[@B19-molecules-17-13960]\], oleanolic acid (**5**) \[[@B20-molecules-17-13960]\], ursolic acid (**6**) \[[@B18-molecules-17-13960]\], cycloart-3*β*, 25-diol (**7**) \[[@B21-molecules-17-13960]\], foliasalacioside B1 (**8**) \[[@B22-molecules-17-13960]\], (6*R*,7*E*,9*R*)-9-hydroxy-4,7-megastigmadien-3-one-9-*O*-*α*-L-arabinopyranosyl-(1→6)-*β*-D-glucopyranoside (**9**) \[[@B23-molecules-17-13960]\], (6*R*,7*E*,9*R*)-9-hydroxy-4,7-megastigmadien-3-one-9-O-*β*-D-xylopyranosyl-(1→6)-*β*-D-glucopyranoside (**10**) \[[@B24-molecules-17-13960]\], and quercetin 3-*O*-sambubioside (**11**) \[[@B11-molecules-17-13960]\] were also identified on the basis of their spectroscopic profiles (NMR, UV, CD and MS) and comparisons to published data.

The *in vitro* inhibition of protein tyrosine phosphatase 1B (PTP1B) activity by compounds **1**--**6**, **8**--**10** was tested at 10 μM*,* with the known effective compound CCCF06240 as positive control \[[@B25-molecules-17-13960]\]. As shown in [Table 2](#molecules-17-13960-t002){ref-type="table"}, compounds **3** and **4** exhibited inhibition to PTPIB activities, with IC~50~ values of 0.69 and 3.98 μM, respectively ([Figure 5](#molecules-17-13960-f005){ref-type="fig"}).

3. Experimental {#sec3-molecules-17-13960}
===============

3.1. General Procedures {#sec3dot1-molecules-17-13960}
-----------------------

Optical rotations were measured on a P2000 automatic digital polarimeter. UV spectra were taken with a Hitachi UV-240 spectrophotometer. CD spectra were measured on a JASCO *J*-815 spectro-polarimeter. IR spectra were recorded on a Nicolet 5700 FT-IR spectrometer. NMR measurements were performed on INOVA-500 and Bruker AV500-III spectrometers. HRESIMS were obtained using an Agilent 1100 series LC/MSD Trap SL mass spectrometer. Preparative HPLC was carried out on a Shimadazu LC-6AD instrument with a SPD-20A detector, using a YMC-Pack ODS-A column (250 × 20 mm, 5 µm). Column chromatography (CC) was performed with silica gel (200--300 mesh, Qingdao Marine Chemical Inc., Qingdao, People's Republic of China) and ODS (50 µm, YMC, Tokyo, Japan). TLC was carried out with glass precoated silica gel GF~254~ plates.

3.2. Plant Material {#sec3dot2-molecules-17-13960}
-------------------

The leaves of *E. ulmoides* were collected in Liuzhou, Guangxi, China, in August 2008, and identified by Associate Professor Lin Ma of the Institute of Materia Medica, Chinese Academy of Medical Science, Beijing, China. A voucher specimen had been deposited at the Herbarium of Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College (200816).

3.3. Extraction and Isolation {#sec3dot3-molecules-17-13960}
-----------------------------

The dried leaves of *E. ulmoides* (2.0 kg) were powdered and extracted with 95% ethanol (30 L × 3) under reflux. The filtrate was evaporated under reduced pressure to yield a dark brown residue (320 g). The residue was suspended in water (2,000 mL) and then successively partitioned with EtOAc (3 × 1,000 mL) and *n*-BuOH (3 × 1,000 mL). After removing the solvent, the EtOAc-soluble portion (120 g) was fractionated via silica gel CC eluting with a CHCl~3~-MeOH gradient (100:0--3:1) to afford ten fractions A~1~-A~10~ on the basis of TLC analysis. Fraction A~2~ (16.301 g) was chromatographed over silica gel (200--300 mesh) eluted with a CHCl~3~-MeOH gradient (100:1, 50:1) to give **2** (25 mg), **3** (8 mg), **4** (8 mg), **5** (450 mg), **6** (360 mg), and **7** (9 mg) and a mixture (20 mg). This mixture was further purified by preparative HPLC on ODS (YMC-pack; eluent: MeCN-H~2~O, 30:70, v/v, 7 mL/min, 210 nm) to afford **1** (t~R~ 54 min, 8 mg). Fraction A~7~ (8.48 g) was chromatographed over silica gel (200--300 mesh) eluted with a CHCl~3~-MeOH gradient (20:1, 8:1, 4:1) to give nine subfractions, A~7~a--A~7~i. Fraction A~7~e was purified by preparative HPLC (YMC-pack; eluent: MeOH-H~2~O, 35:65, v/v, 7 mL/min, 254 nm) to yield **11** (t~R~ 37 min, 15 mg). Fraction A~7~f was purified by preparative HPLC (YMC-pack; eluent: MeOH-H~2~O, 50:50, v/v, 7 mL/min, 210 nm) to yield **8** (t~R~ 45 min, 10 mg), **9** (t~R~ 55 min, 9 mg), and **10** (t~R~ 67 min, 7 mg).

3.4. Spectral Data {#sec3dot4-molecules-17-13960}
------------------

*Ulmoidol A* (**1**). White amorphous powder, $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{20}$ + 7.56 (*c* 0.08, MeOH); UV (MeOH) *λ* ~max~ (log *ε*) 208 (2.54), 258 (4.21) nm; IR *ν*~max~ cm^−1^: 3,407, 2,935, 1,784, 1,618, 1,241, and 937. ESIMS *m/z*: 489 \[M+Na\]^+^, 467 \[M+H\]^+^; HRESIMS *m/z*: 467.2804 \[M+H\]^+^ (calcd. 467.2792, C~2~α~9~H~39~O~5~). For ^1^H and ^13^C-NMR spectroscopic data, see [Table 1](#molecules-17-13960-t001){ref-type="table"}.

3.5. PTP1B Activity Assay *\[[@B25-molecules-17-13960]\]* {#sec3dot5-molecules-17-13960}
---------------------------------------------------------

Recombinant human GST-PTP1B protein was overexpressed by hGST-PTP1B-BL21 *E. coli* and purified by GST affinity chromatography. The reagent pNPP was used as substrate for the measurement of PTP1B activity. Compounds were pre-incubated with the enzyme at room temperature for 5 min. Assay was performed in final volume of 100 μL in the active system containing 50 Mm HEPES, 5 mM DTT, 150 mM NaCl, 2 mM EDTA, and 2 mM pNPP (pH 7.0), incubated at 30 °C for 10 min, stopped by addition of 50 μl 3 M NaOH. Then, the absorbance was determined at 405 nm wavelength. The similar system without GST-PTP1B protein was used as blank. The effects of compounds **1**--**6**, **8**--**10** on PTP1B activity were measured, and the IC50 value was calculated by nonlinear regression.

4. Conclusions {#sec4-molecules-17-13960}
==============

A new ursane-type nortriterpenoid, ulmoidol A (**1**), together with ten known compounds were isolated from the leaves of *Eucommia ulmoides* Oliv. The structure of compound **1** was determined by extensive spectroscopic analysis, and the absolute configuration was determined by CD experiments and computational methods. Compounds **3**, **4**, **7**--**10** were isolated from this plant for the first time. Compounds **1**--**6**, and **8**--**10** were tested for inhibition of `PTP1B` activities, and compounds **3** and **4** showed inhibit activities with IC~50~ values of 0.69 and 3.98 μM, respectively.
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molecules-17-13960-t001_Table 1

###### 

NMR data of compound **1** in CDCl~3~ (500 MHz for ^1^H-NMR and 125 MHz for ^13^C-NMR).

  -------------------------------------------
  Position   ^1^H                    ^13^C
  ---------- ----------------------- --------
  1          6.47 s                  123.22

  2                                  144.88

  2-OH       6.23 s                  

  3                                  181.44

  4                                  127.34

  5                                  163.62

  6          2.50 (td, 13.5, 4.5)\   24.10
             2.80 (brd, 13.5)        

  7          1.39 m\                 31.93
             1.26 m                  

  8                                  41.68

  9          1.75 (brs)              47.72

  10                                 41.91

  11         3.38 (dd, 4.0, 2.0)     54.71

  12         3.08 (d, 4.0)           56.60

  12                                 

  13                                 88.67

  14                                 41.68

  15         1.11(dd,14.0,5.5)\      27.20
             1.74 m                  

  16         2.13 (td, 13.5, 5.5)\   22.68
             1.37 m                  

  17                                 45.10

  18         1.79 m                  60.46

  19         0.97 m                  40.20

  20         1.67m                   37.50

  21         1.60 m1.25 m            30.49

  22         1.81 m\                 31.32
             1.53 (td, 13.5, 4.5)    

  23         2.01 s                  10.89

  25         1.40 s                  22.44

  26         1.33 s                  19.13

  27         0.97 s                  16.21

  28                                 178.83

  29         1.18 (d, 6.5)           17.16

  30         0.98 (d, 5.5)           19.46
  -------------------------------------------

molecules-17-13960-t002_Table 2

###### 

The inhibition to PTP1B activities of compounds **1**--**6**, **8**--**10**.

  Comp.           Inhibition (%) at 10 μM
  --------------- -------------------------
  1               4.8
  2               3.0
  3               81.3
  4               79.8
  5               28.3
  6               43.5
  8               13.4
  9               28.6
  10              17.8
  CCCFO6240 ^a^   108.5

^a^ Positive control.
